Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | CPX-351 vs 7+3 in older high-risk AML patients

Thomas Prebet • 11 Jun 2020
EHA 2020
Leukemia CPX-351 Cytarabine Daunorubicin

Thomas Prebet, MD, of the Yale School of Medicine, New Haven, CT, discusses the results of an exploratory analysis of the efficacy and safety of CPX-351 versus 7+3 in a Phase III study (NCT01696084) of older adults with high-risk/secondary acute myeloid leukemia (AML). Dr Prebet also highlights the importance of TP53 mutational status as a prognostic marker for success for patients in both treatment arms. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Thomas Prebet

Risk stratified analysis of CPX-351 versus 7 + 3 in older adults with AML
3:31
Risk stratified analysis of CPX-351 versus 7 + 3 in older adults with AML
Thomas Prebet • 18 Nov 2020
Hypomethylating agent based combinations in MDS
1:50
Hypomethylating agent based combinations in MDS
Thomas Prebet • 18 Nov 2020
AML: what to look forward to at ASH 2020
2:19
AML: what to look forward to at ASH 2020
Thomas Prebet • 18 Nov 2020
New treatments for AML
1:19
New treatments for AML
Thomas Prebet • 7 Oct 2020

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals